## CLAIMS

1. Use of an anti-Gremlin-1 antibody in the manufacture of a medicament for treating or preventing a cancer having stromal GREM1 overexpression, wherein the anti-Gremlin-1 antibody comprises a HCDR1 (heavy chain complementarity determining region)/HCDR2/HCDR3/LCDR1 (light chain complementarity determining region) /LCDR2/LCDR3 sequence combination of SEQ ID NOs: 4/5/6/7/8/9 or SEQ ID NOs: 3/5/6/7/8/9, and

wherein the antibody has a dissociation constant ($K_D$) of less than 500 pM, 200 pM or 100 pM for human Gremlin-1.

2. Use according to claim 1, wherein the cancer is a solid cancer.

3. Use according to claim 1 or claim 2, wherein the cancer is selected from colorectal cancer, multiple myeloma, pancreatic cancer, bladder cancer, breast cancer, lung cancer, stomach cancer, duodenal cancer, oesophageal cancer, head and neck cancer, prostate cancer, glioma, endometrial cancer, liver cancer, spleen cancer, bone-resident cancer, and osteosarcoma.

4. Use according to claim 3, wherein:

(a) the cancer is colorectal cancer; further optionally wherein the colorectal cancer is a mesenchymal subtype colorectal cancer;

(b) the cancer is multiple myeloma; or

(c) the cancer is breast cancer;

5. Use according to any one of claims 1 to 4, wherein:

(a) the cancer has epithelial GREM1 overexpression; optionally wherein the cancer is a GREM1-initiated cancer;

(b) the cancer is a disseminated cancer; and/or

(c) the cancer is an established cancer, optionally wherein the established cancer is an established colorectal cancer.

6. Use according to any one of claims 1 to 5, wherein the anti-Gremlin-1 antibody comprises a heavy chain variable region (HCVR) sequence of SEQ ID NO: 10 or 12 and/or a light chain variable region (LCVR) sequence of SEQ ID NO: 11 or 13, or sequences which are at least 95% identical thereto.

7. Use according to claim 6, wherein:

(a) the anti-Gremlin-1 antibody comprises a HCVR and LCVR sequence pair of SEQ ID NOs: 10/11 or 12/13 or sequences which are at least 95% identical thereto; and/or

(b) the anti-Gremlin-1 antibody comprises a heavy chain of SEQ ID NO: 14, 16, 18, 22, 28, 30, 32 or 34 and/or a light chain of SEQ ID NO: 15, 17, 19, 23, 29, 31, 33 or 35, or sequences which are at least 95% identical thereto.

8. Use according to claim 7(b), wherein the anti-Gremlin-1 antibody comprises a heavy and light chain pair of SEQ ID NOs: 14/15, 16/17, 18/19, 22/23, 28/29 or 30/31, 32/33, 34/35, or sequences which are at least 95% identical thereto.

9. Use according to any one of claims 1 to 8, wherein:

(a) the antibody is a chimeric, human or humanised antibody; and/or

(b) the antibody is a Fab, modified Fab, Fab', modified Fab', $F(ab')_2$, Fv, single domain antibody or an scFv.

10. Use according to any one of claims 1 to 9, wherein the antibody is comprised in pharmaceutical composition further comprising a pharmaceutically acceptable adjuvant and/or carrier.

11. Use according to any one of claims 1 to 10, wherein:

(a) the medicament is to be administered with an additional anti-cancer agent separately, sequentially or simultaneously; optionally wherein said additional anti-cancer agent is a chemotherapeutic agent; and/or

(b) the medicament is to be administered separately, sequentially or simultaneously with radiotherapy.

12. Use of an anti-cancer agent in the manufacture of a medicament for treating a cancer having stromal GREM1 overexpression wherein the medicament is to be administered separately, sequentially or simultaneously with an anti-Gremlin-1 antibody as defined in any one of claims 1 to 11.

13. Use according to claim 12, wherein:

(a) said anti-cancer agent is a chemotherapeutic agent; and/or

(b) said cancer, and/or said treatment are as defined in any one of claims 1-11(a).

14. A composition or kit comprising an anti-Gremlin-1 antibody as defined in any one of claims 1 to 13 and an additional anti-cancer agent.

15. A composition or kit according to claim 14, wherein the additional anti-cancer agent is a chemotherapeutic agent.

16. The composition or kit of claim 14 or claim 15, wherein:

(a) said anti-cancer or chemotherapeutic agent is suitable for treatment of colorectal cancer, optionally selected from 5-fluoruracil, oxaliplatin, irinotecan, folinic acid, cetuximab, nivolumab or bevacizumab; or

(b) said anticancer or chemotherapeutic agent is suitable for treatment of multiple myeloma, optionally selected from an anti-CD38 antibody (such as daratumumab), an anti-SLAMF7 antibody (such as elotuzumab), an anti-IL-6 antibody (such as siltuximab), or bortezumib or iMID (lenalidomide/pomalenomide).

17. A method for detecting cancer in a patient, the method comprising measuring stromal expression of GREM1 in a sample obtained from the patient using an anti-Gremlin-1 antibody according to any one of claims 1 to 11, wherein stromal overexpression of GREM1 indicates that the patient comprises a cancer.

18. A method for prognosing a cancer in a patient, the method comprising determining whether or not a cancer biopsy obtained from the patient comprises stromal overexpression of GREM1 using an anti-Gremlin-1 antibody according to any one of claims 1 to 11, wherein stromal overexpression of GREM1 in the cancer biopsy indicates that the patient has a worse prognosis than in the situation of normal stromal expression of GREM1.

19. A method for determining whether or not a patient having or suspected of having or being at risk of developing cancer is likely to respond to treatment with a combination therapy comprising an anti-Gremlin-1 antibody according to any one of claims 1 to 11 and a chemotherapeutic agent, which method comprises measuring stromal expression of GREM1 in a sample obtained from the patient, and thereby predicting whether or not the patient is likely to respond to treatment with the combination therapy.

20. A method for determining whether or not a patient having or suspected of having or being at risk of developing cancer is likely to respond to treatment with an anti-Gremlin-1 antibody according to any one of claims 1 to 11, the method comprising measuring stromal expression of GREM1 in a sample obtained from the patient, and thereby predicting whether or not the patient is likely to respond to treatment with the anti-Gremlin-1 antibody.